Acadia Pharmaceuticals Inc (ACAD) Inventory Turnover Ratio, from second quarter 2026 to second quarter 2025, current and historic results, rankings and more, Quarterly Fundamentals - CSIMarket
CSIMarket Company Name, Ticker, Customers, else..
 
Acadia Pharmaceuticals Inc   (NASDAQ: ACAD)
 

Acadia Pharmaceuticals Inc Inventory Turnover Ratio (COS)

Cost of Sales Formula, Quarterly Results, Trends, Rankings, Statistics

Acadia Pharmaceuticals Inc inventory turnover ratio, the Acadia Pharmaceuticals Inc 's ability to sell and replace its inventory in the second quarter 2026, sequentially increased to 1.07 in the second quarter 2026, yet the ratio remained below the average, as ACAD's market remain challenging.Average inventory processing period, for the Acadia Pharmaceuticals Inc in Jun 30 2026 quarter, has decreased to 341 days, compare to 344 days, in the Mar 31 2026 quarter.

Within Healthcare sector 306 other companies have achieved higher inventory turnover ratio. While in terms of ranking among all other companies, the company has moved form 1434 in the first quarter 2026, to 1826.

ACAD Inventory Turnover Ratio using Sales Formula
What is Inventory Turnover Ratio?
What is Acadia Pharmaceuticals Inc Market Share?

What is Inventory Turnover Ratio?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

ACAD Inventory Turnover Ratio (Jun 30 2026)
II. Quarter		 (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter
Y / Y Inventory Growth 28.76 % 0.87 % 21.47 % 199.19 % 480.32 %
Y / Y Cost of Sales Growth 36.57 % 21.57 % 20.28 % 14.8 % 13.74 %
Inventory Turnover Ratio (TTM) 1.07 1.06 1.01 1.02 1.16
ACAD's Total Ranking # 1826 # 1434 # 0 # 683 # 1006
Average inventory processing period 341 345 362 359 314
Seq. Inventory Growth 34.63 % -27.52 % 44.85 % -8.9 % 5.47 %
Seq. Cost of Sales Growth 14.22 % -5.47 % 21.15 % 4.4 % 1.68 %




Inventory Turnover Ratio Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 88
Healthcare Sector # 307
Overall Market # 1826

Inventory Turnover Ratio Statistics
High Average Low
13.33 2.67 0.95
(Mar 31 2024)   (Jun 30 2021)



ACAD Company Profile >> Back to ACAD Efficiency Comparisons >> Compare ACAD Inventory Turnover Ratio to its Competitors

Financial Statements
Acadia Pharmaceuticals Inc 's Inventories $ 109 Millions Visit ACAD's Balance sheet
Acadia Pharmaceuticals Inc 's Cost of Revenues TTM $ 101 Millions Visit ACAD's Income Statement
What are ACAD's Sales? Visit ACAD's Sales by Segment

Other Inventory Turnover Ratios
Acadia Pharmaceuticals Inc 's Inventory to Sales Ratio
U.S. Durable Goods Inventory to Shipment Ratio By Product
Major Pharmaceutical Preparations Industry Inventory Turnover Trends and Statistics
Healthcare Sector Inventory Turnover Statistics
Inventory Turnover Trends for overall market
ACAD's Inventory Turnover Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Inventory Turnover
Lowest Ranking Inventory Turnover
Inventory Turnover for ACAD's Competitors
Inventory Turnover Ratio for ACAD's Suppliers
Inventory Turnover Ratio for ACAD's Customers

You may also want to know
ACAD's Sales Growth Rates ACAD's Pe Price to earnings ratio ACAD's Receivables Turnover Ratio ACAD's Stock Quote
ACAD's Net Income Growth Rates ACAD's Ps Price to Sales ratio ACAD's Sales per Employee ACAD's Asset Turnover Ratio
ACAD's Net Margin ACAD's Pb Price to Book ratio ACAD's Financial Strength Ratios ACAD's Dividend Payout Ratio



Companies with similar Inventory Turnover Ratio for the quarter ending Jun 30 2026, within Healthcare Sector Inventory Turnover Ratio Cost of revenues at quarter ending Jun 30 2026 Inventories at quarter ending Jun 30 2026
Indivior Pharmaceuticals Inc   2.55 $ 240.000  Millions$ 94  Millions
Nephros Inc   2.54 $ 8.991  Millions$ 4  Millions
Illumina Inc   2.52 $ 1,510.000  Millions$ 599  Millions
IMPACT BIOMEDICAL INC.  2.46 $ 0.414  Millions$ 0  Millions
Quidelortho Corp  2.45 $ 1,481.500  Millions$ 605  Millions
Cumberland Pharmaceuticals Inc   2.44 $ 5.164  Millions$ 2  Millions
Perrigo Company Plc  2.43 $ 2,775.900  Millions$ 1,140  Millions
Pro dex Inc   2.43 $ 53.213  Millions$ 22  Millions
Angiodynamics Inc   2.43 $ 142.834  Millions$ 59  Millions
Cytosorbents Corporation  2.43 $ 10.584  Millions$ 4  Millions
Journey Medical Corp  2.42 $ 23.556  Millions$ 10  Millions
Aquestive Therapeutics Inc   2.42 $ 17.828  Millions$ 7  Millions
Viatris Inc   2.41 $ 9,604.200  Millions$ 3,993  Millions
Electrocore Inc   2.40 $ 4.346  Millions$ 2  Millions
United Therapeutics Corporation  2.39 $ 437.200  Millions$ 183  Millions
Cannapharmarx Inc   2.37 $ 2.483  Millions$ 1  Millions
Resmed Inc   2.35 $ 2,188.346  Millions$ 933  Millions
Aurinia Pharmaceuticals Inc   2.34 $ 30.036  Millions$ 13  Millions
Fortress Biotech Inc   2.34 $ 22.768  Millions$ 10  Millions
Scientific Industries Inc   2.33 $ 4.057  Millions$ 2  Millions
Insight Molecular Diagnostics Inc   2.31 $ 0.868  Millions$ 0  Millions
Merit Medical Systems Inc  2.30 $ 798.467  Millions$ 347  Millions
Tela Bio Inc   2.30 $ 26.348  Millions$ 11  Millions
Sanara Medtech Inc   2.29 $ 7.981  Millions$ 3  Millions
China Pharma Holdings Inc  2.25 $ 3.450  Millions$ 2  Millions
Beta Bionics Inc   2.23 $ 50.111  Millions$ 22  Millions
Apyx Medical Corp  2.21 $ 21.014  Millions$ 10  Millions
Medtronic Plc  2.21 $ 13,136.000  Millions$ 5,950  Millions
Caredx Inc   2.20 $ 48.623  Millions$ 22  Millions
Embecta Corp   2.19 $ 418.400  Millions$ 191  Millions

Date modified: 2026-10-05T11:03:41+00:00




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.